Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Zahra AlHaj Issa, Cristiano Machado De Freitas, Aarya Murali, Akhil Rajendra, Dawn Maze, Aniket Banker, Steven Chan, Marta Davidson, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen W.L. Yee, Mark Minden, Vikas Gupta, Maria Perusini, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2025-3390

Published: 2025

Journal Articles

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Yael Morgenstern, Claire Andrews, Eshetu Atenafu, Steven Chan, Vikas Gupta, Mark Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2025-3388

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra AlHaj Issa, Aniket Bankar, Hassan Sibai, Maria Perusini, Aaron Schimmer, Mark Minden, Steven Chan, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Marta Davidson, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2025-4776

Published: 2025

Journal Articles

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan, Aniket Bankar, Jonathan Wei, Marta Davidson, Guillaume Richard-Carpentier, Mark Minden, Andre Schuh, Karen W.L. Yee, Vikas Gupta, Dawn Maze, Steven Chan, Aaron Schimmer, Claire Andrews, Hassan Sibai, Maria Perusini

Blood (2025) 146 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2025-3330

Published: 2025

Journal Articles

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Elizabeth Herrity, Dawn Maze, Marta Davidson, Aniket Bankar, Maria Perusini, Hassan Sibai, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2025-5240

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only